$0.707
-0.006 (-0.81%)收盤時
IRIX 資訊
IRIX 事件
Iridex Partners with EyeProGPO for Laser Pricing
Iridex announced a new partnership with EyeProGPO. Through this partnership, the 1,800 plus EyeProGPO members can receive preferred pricing on the Iridex Pascal laser platform, IQ 532 and IQ 577 lasers, and the OcuLight TX laser.
Iridex Relocates Headquarters to San Jose, Expects $400K Savings
Iridex announced its intent to relocate the Company's headquarters from Mountain View, California to San Jose, California. On January 26, 2026, the Company signed a non-binding letter of intent for a new lease. The Company plans to move to the 31,000 square feet location and is expecting to generate savings of approximately $0.4 million in fiscal year 2026 and approximately $0.6 million in savings on an annualized basis thereafter. The terms of the Lease remain subject to change, and the Company cannot provide any guarantee that the Lease will be executed upon these same terms or at all.
IRIDEX Expects Total Revenue of $14.6M to $14.8M in 2025
Total revenue is expected to be between $14.6 million and $14.8 million compared to $12.7 million in the prior year quarter, representing year-over-year growth between 15% and 17%. "In 2025, we strengthened our financial position through focused cost reductions, gross margin expansion, and improved commercial efficiency, and increased probe sales," said Patrick Mercer, President and CEO of IRIDEX. "When we set and communicated our goals for 2025, we were clear about what we intended to accomplish-and in 2025 we delivered. The actions we took drove a fifth consecutive quarter of year-over-year revenue growth, reduced operating expenses, and improved adjusted EBITDA. We achieved positive cash flow in the fourth quarter of 2025, and we expect to achieve positive adjusted EBITDA for the full year 2025."
Iridex Study Shows 25%-35% IOP Reduction in Glaucoma Patients Using MicroPulse Technology
Iridex announced a recently published independent, retrospective study in Ophthalmology and Therapy. The study demonstrates that retreatment of transscleral laser treatment using MicroPulse technology can safely and effectively further reduce intraocular pressure, or IOP, in patients with glaucoma. The study aimed to assess the effectiveness, repeatability, and safety of retreatment in real-world clinical practice using MicroPulse TLT. Three months after retreatment, all patient groups demonstrated meaningful IOP reductions, ranging from approximately 25% to 35%, regardless of their prior response to the primary treatment. Retreatment timing varied widely across patient groups, reflecting the individualized nature of glaucoma management. On average, patients received their first retreatment as early as approximately 4 months in nonresponders and as late as more than 28 months in patients with late-attrition. Among the subset of patients who required a second retreatment, intervals ranged from about 3 months to nearly 2 years in enhancement cases.
Iridex Publishes Study on Laser Treatments for Glaucoma
Iridex announced a newly published study in Translational Vision Science & Technology, TVST, examining the thermal dynamics of transscleral laser treatments for glaucoma. Led by Tomas M. Grippo, MD, of the Grippo Glaucoma & Cataract Center, the study provides the first quantitative computer model comparing the thermal tissue effects of continuous wave transscleral cyclophotocoagulation, CW-TSCPC, and transscleral laser therapy using MicroPulse technology with Iridex's Cyclo G6 Laser, G-Probe and MicroPulse P3 delivery devices. Using advanced Monte Carlo computer simulations, the authors modeled how each technique heats the ciliary body and quantified temperature peaks, duration, and thermal spread. The modeling revealed that CW TSCPC produced a 2 mm-wide zone of tissue heating with temperatures exceeding 100 degrees C for approximately 2.2 seconds. MicroPulse TLT generated a smaller 0.6-1.2 mm thermal zone and shorter duration peak temperatures, remaining below 100 degrees C. Additionally, MicroPulse TLT showed a more uniform heat distribution than CW-TSCPC.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。